TNFSF10 and diabetes mellitus: Recently, TRAIL is increasingly studied in the context of nonmalignant diseases, specifically metabolic diseases such as obesity, type 2 diabetes mellitus, and cardiovascular disease.10, 11 Choi et al.12 demonstrated that circulating TRAIL levels correlate positively with the body mass index (BMI) and serum lipid levels.